Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, ...

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose ...

“Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths – NARCAN® Nasal Spray 4 mg and KLOXXADO® Nasal Spray 8 mg – allows ...

Emergent BioSolutions Inc. (NYSE: EBS), a pharmaceutical company with a market capitalization of approximately $510 million, has acquired exclusive commercial rights for KLOXXADO® (naloxone HCl ...

KLOXXADO is a prescription 8 mg naloxone nasal spray designed for the emergency treatment of opioid overdose. The agreement expands Emergent's portfolio of life-saving opioid overdose treatments ...